What is Bioject Medical Technologies Sloan Ratio %?
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Sep. 2011, Bioject Medical Technologies has a Sloan Ratio of -0.99%, indicating the company is in the safe zone and there is no funny business with accruals.
Bioject Medical Technologies Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bioject Medical Technologies's Sloan Ratio %
For the Medical Instruments & Supplies subindustry, Bioject Medical Technologies's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioject Medical Technologies's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioject Medical Technologies's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Bioject Medical Technologies's Sloan Ratio % falls into.
Bioject Medical Technologies Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Bioject Medical Technologies's Net Income for the trailing twelve months (TTM) ended in Sep. 2011 was -0.043 (Dec. 2010 ) + -0.156 (Mar. 2011 ) + 0.274 (Jun. 2011 ) + 0.398 (Sep. 2011 ) = $0.47 Mil.
Bioject Medical Technologies's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2011 was -0.01 (Dec. 2010 ) + 0.293 (Mar. 2011 ) + 0.284 (Jun. 2011 ) + 0.094 (Sep. 2011 ) = $0.66 Mil.
Bioject Medical Technologies's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2011 was -0.094 (Dec. 2010 ) + -0.021 (Mar. 2011 ) + -0.056 (Jun. 2011 ) + 0.029 (Sep. 2011 ) = $-0.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioject Medical Technologies (OTCPK:BJCT) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Sep. 2011, Bioject Medical Technologies has a Sloan Ratio of -0.99%, indicating the company is in the safe zone and there is no funny business with accruals.
Bioject Medical Technologies Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Bioject Medical Technologies's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Bioject Medical Technologies (Bioject Medical Technologies) Business Description
Bioject Medical Technologies Inc commenced operations in 1985 and is a developer and manufacturer of needle-free injection therapy systems (NFITS). The Companys long-term goal is to become supplier of needle-free injection systems to the pharmaceutical and biotechnology industries. It focused its business development efforts on new and existing licensing and supply agreements with pharmaceutical and biotechnology companies, as well as numerous research agreements that could guide to long-term agreements. The Companys pipeline of prospective new partnerships remains active. It is also actively pursuing additional opportunities both domestically and overseas as it expands its current product line. The Companys Biojector 2000 system (B2000) consists of two components: a hand-held, reusable jet injector and a sterile, single-use, disposable plastic syringe capable of delivering variable doses of medication up to 1.0 mL. Drug Reconstitution System - The needle-free drug reconstitution system allows for the transfer of diluents to reconstitute powdered medications into liquid form and withdrawal of liquid medication into a syringe without the use of a needle. Vitajet - The Vitajet is also composed of two components, a portable injector unit and a disposable syringe. It is smaller and lower in cost than other products in its needle-free offering. ZetaJet - The ZetaJet is Biojects latest advance in needle-free delivery systems. It consists of two components, the portable injector and an auto-disabling disposable syringe. The medical equipment market is very competitive. Bioject Medical Technologies has two patents: Biojector 2000 and Vitajet. The Companys products and manufacturing operations are subject to extensive government regulations, both in the U.S. and abroad. In the U.S., the Food and Drug Administration (FDA) administers the Federal Food, Drug and Cosmetic Act (FFDCA) and has adopted regulations to administer the FFDCA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BJCT has been successfully added to your 